||Recombinant Human CFC1 (Accession # NP_115934), fused with , was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
||Measured by its ability to cause heart reversals when injected into the right lateral plate of a population of Xenopus neurulae embryos. 80 ng per embryo typically induces 25 - 50% heart reversals.Measured by its ability to inhibit the cell growth of DU145 human prostate carcinoma cells. Miyazaki, H. et al. (2004) Oncogene 23:9326.The ED50 for this effect is typically 1.5 - 7.5 µg/mL.
||Recombinant Human CFC1 has a calculated MW of 17.4 kDa. In SDS-PAGE migrates as 24 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).